Vertex Pharmaceuticals Net Worth
Vertex Pharmaceuticals Net Worth Breakdown | VRTX |
Vertex Pharmaceuticals Net Worth Analysis
Vertex Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Vertex Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Vertex Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Vertex Pharmaceuticals' net worth analysis. One common approach is to calculate Vertex Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Vertex Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Vertex Pharmaceuticals' net worth. This approach calculates the present value of Vertex Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Vertex Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Vertex Pharmaceuticals' net worth. This involves comparing Vertex Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Vertex Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Vertex Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vertex Pharmaceuticals' net worth research are outlined below:
| Vertex Pharmaceuticals generated a negative expected return over the last 90 days | |
| Vertex Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 97.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from newsbtc.com: Vertex AI Price Forecast Bitcoin Has 60 percent Chance Of Hitting 100,000, Key Predictions Unveiled |
Vertex Pharmaceuticals Quarterly Good Will |
|
Vertex Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vertex Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vertex Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of February 2024 Upcoming Quarterly Report | View | |
| 6th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Vertex Pharmaceuticals Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vertex target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Vertex Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 33 | Buy |
Most Vertex analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Vertex stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Vertex Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationVertex Pharmaceuticals Target Price Projection
Vertex Pharmaceuticals' current and average target prices are 397.48 and 388.67, respectively. The current price of Vertex Pharmaceuticals is the price at which Vertex Pharmaceuticals is currently trading. On the other hand, Vertex Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Vertex Pharmaceuticals Market Quote on 28th of April 2024
Target Price
Analyst Consensus On Vertex Pharmaceuticals Target Price
Know Vertex Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vertex Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vertex Pharmaceuticals backward and forwards among themselves. Vertex Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Vertex Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Massachusetts Financial Services Company | 2023-12-31 | 3.6 M | Capital Research Global Investors | 2023-12-31 | 3.6 M | Loomis, Sayles & Company Lp | 2023-12-31 | 3.1 M | Norges Bank | 2023-12-31 | 3 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 3 M | Goldman Sachs Group Inc | 2023-12-31 | 3 M | Amundi | 2023-12-31 | 2.7 M | Northern Trust Corp | 2023-12-31 | 2.7 M | Ubs Asset Mgmt Americas Inc | 2023-12-31 | 2.6 M | Vanguard Group Inc | 2023-12-31 | 22.3 M | Blackrock Inc | 2023-12-31 | 21.9 M |
Follow Vertex Pharmaceuticals' market capitalization trends
The company currently falls under 'Mega-Cap' category with a current market capitalization of 102.73 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vertex Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Vertex Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Project Vertex Pharmaceuticals' profitablity
Vertex Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Vertex Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Vertex Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Vertex Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Vertex Pharmaceuticals' profitability requires more research than a typical breakdown of Vertex Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.17 | 0.18 | |
| Return On Capital Employed | 0.20 | 0.21 | |
| Return On Assets | 0.16 | 0.17 | |
| Return On Equity | 0.21 | 0.22 |
When accessing Vertex Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Vertex Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vertex Pharmaceuticals' profitability and make more informed investment decisions.
The data published in Vertex Pharmaceuticals' official financial statements usually reflect Vertex Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Vertex Pharmaceuticals. For example, before you start analyzing numbers published by Vertex accountants, it's critical to develop an understanding of what Vertex Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Vertex Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vertex Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Vertex Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vertex Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Vertex Pharmaceuticals' management manipulating its earnings.
Evaluate Vertex Pharmaceuticals' management efficiency
Vertex Pharmaceuticals has return on total asset (ROA) of 0.1317 % which means that it generated a profit of $0.1317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2299 %, meaning that it created $0.2299 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.18 in 2024. Return On Capital Employed is likely to rise to 0.21 in 2024. At this time, Vertex Pharmaceuticals' Return On Assets are fairly stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 68.22 | 71.63 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 60.74 | 63.78 | |
| Enterprise Value Over EBITDA | 24.24 | 23.03 | |
| Price Book Value Ratio | 5.96 | 7.46 | |
| Enterprise Value Multiple | 24.24 | 23.03 | |
| Price Fair Value | 5.96 | 7.46 | |
| Enterprise Value | 15.8 B | 8.3 B |
The analysis of Vertex Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Vertex Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Vertex Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 9.3342 | Revenue 9.9 B | Quarterly Revenue Growth 0.093 | Revenue Per Share 38.297 | Return On Equity 0.2299 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vertex Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vertex Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vertex Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Charles Wagner over three months ago Sale by Charles Wagner of 3000 shares of Vertex Pharmaceuticals | ||
Charles Wagner over a year ago Payment of 2707 shares by Charles Wagner of Vertex Pharmaceuticals subject to Rule 16b-3 |
Vertex Pharmaceuticals Corporate Filings
| 22nd of April 2024 Other Reports | ViewVerify | |
F4 | 17th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 16th of April 2024 Other Reports | ViewVerify | |
8K | 11th of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Vertex Pharmaceuticals Earnings Estimation Breakdown
The calculation of Vertex Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Vertex Pharmaceuticals is estimated to be 4.07 with the future projection ranging from a low of 3.61 to a high of 4.44. Please be aware that this consensus of annual earnings estimates for Vertex Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
3.61 Lowest | Expected EPS | 4.44 Highest |
Vertex Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Vertex Pharmaceuticals' value are higher than the current market price of the Vertex Pharmaceuticals stock. In this case, investors may conclude that Vertex Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Vertex Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2024 | Current EPS (TTM) | |
| 27 | 96.26% | 4.2 | 4.07 | 13.87 |
Vertex Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Vertex Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Vertex Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Vertex Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Vertex Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Vertex Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Vertex Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Vertex Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Vertex Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-02-05 | 2023-12-31 | 4.1 | 4.2 | 0.1 | 2 | ||
2023-11-06 | 2023-09-30 | 3.97 | 4.08 | 0.11 | 2 | ||
2023-08-01 | 2023-06-30 | 3.88 | 3.89 | 0.01 | 0 | ||
2023-05-01 | 2023-03-31 | 3 | 3.05 | 0.05 | 1 | ||
2023-02-07 | 2022-12-31 | 3.51 | 3.76 | 0.25 | 7 | ||
2022-10-27 | 2022-09-30 | 3.64 | 4.01 | 0.37 | 10 | ||
2022-08-04 | 2022-06-30 | 3.48 | 3.6 | 0.12 | 3 | ||
2022-05-05 | 2022-03-31 | 3.49 | 3.52 | 0.03 | 0 | ||
2022-01-26 | 2021-12-31 | 3.3 | 3.37 | 0.07 | 2 | ||
2021-11-02 | 2021-09-30 | 3.08 | 3.56 | 0.48 | 15 | ||
2021-07-29 | 2021-06-30 | 2.51 | 3.11 | 0.6 | 23 | ||
2021-04-29 | 2021-03-31 | 2.69 | 2.98 | 0.29 | 10 | ||
2021-02-01 | 2020-12-31 | 2.59 | 2.51 | -0.08 | 3 | ||
2020-10-29 | 2020-09-30 | 2.34 | 2.64 | 0.3 | 12 | ||
2020-07-30 | 2020-06-30 | 2.07 | 2.61 | 0.54 | 26 | ||
2020-04-29 | 2020-03-31 | 1.85 | 2.56 | 0.71 | 38 | ||
2020-01-30 | 2019-12-31 | 1.21 | 1.7 | 0.49 | 40 | ||
2019-10-30 | 2019-09-30 | 1.15 | 1.23 | 0.08 | 6 | ||
2019-07-31 | 2019-06-30 | 1.07 | 1.26 | 0.19 | 17 | ||
2019-04-30 | 2019-03-31 | 0.97 | 1.14 | 0.17 | 17 | ||
2019-02-05 | 2018-12-31 | 1.06 | 1.3 | 0.24 | 22 | ||
2018-10-24 | 2018-09-30 | 1.02 | 1.09 | 0.07 | 6 | ||
2018-07-25 | 2018-06-30 | 0.75 | 0.94 | 0.19 | 25 | ||
2018-04-26 | 2018-03-31 | 0.63 | 0.76 | 0.13 | 20 | ||
2018-01-31 | 2017-12-31 | 0.53 | 0.61 | 0.08 | 15 | ||
2017-10-25 | 2017-09-30 | 0.31 | 0.53 | 0.22 | 70 | ||
2017-07-26 | 2017-06-30 | 0.35 | 0.39 | 0.04 | 11 | ||
2017-04-27 | 2017-03-31 | 0.39 | 0.41 | 0.02 | 5 | ||
2017-01-25 | 2016-12-31 | 0.29 | 0.35 | 0.06 | 20 | ||
2016-10-25 | 2016-09-30 | 0.18 | 0.16 | -0.02 | 11 | ||
2016-07-27 | 2016-06-30 | 0.21 | 0.24 | 0.03 | 14 | ||
2016-04-27 | 2016-03-31 | 0.29 | 0.09 | -0.2 | 68 | ||
2016-01-27 | 2015-12-31 | 0.17 | 0.17 | 0.0 | 0 | ||
2015-10-28 | 2015-09-30 | -0.28 | -0.13 | 0.15 | 53 | ||
2015-07-29 | 2015-06-30 | -0.58 | -0.54 | 0.04 | 6 | ||
2015-04-29 | 2015-03-31 | -0.75 | -0.83 | -0.08 | 10 | ||
2015-01-28 | 2014-12-31 | -0.65 | -0.74 | -0.09 | 13 | ||
2014-10-28 | 2014-09-30 | -0.62 | -0.72 | -0.1 | 16 | ||
2014-07-29 | 2014-06-30 | -0.71 | -0.68 | 0.03 | 4 | ||
2014-05-01 | 2014-03-31 | -0.68 | -1.0 | -0.32 | 47 | ||
2014-01-29 | 2013-12-31 | -0.55 | 0.19 | 0.74 | 134 | ||
2013-10-29 | 2013-09-30 | -0.34 | -0.54 | -0.2 | 58 | ||
2013-07-29 | 2013-06-30 | -0.19 | -0.26 | -0.07 | 36 | ||
2013-04-30 | 2013-03-31 | -0.18 | -0.11 | 0.07 | 38 | ||
2013-01-29 | 2012-12-31 | -0.08 | -0.09 | -0.01 | 12 | ||
2012-11-01 | 2012-09-30 | 0.2 | -0.27 | -0.47 | 235 | ||
2012-07-30 | 2012-06-30 | 0.58 | 0.06 | -0.52 | 89 | ||
2012-04-26 | 2012-03-31 | 0.56 | 0.43 | -0.13 | 23 | ||
2012-02-02 | 2011-12-31 | 0.7 | 0.74 | 0.04 | 5 | ||
2011-10-27 | 2011-09-30 | 0.21 | 1.02 | 0.81 | 385 | ||
2011-07-28 | 2011-06-30 | -0.96 | -0.85 | 0.11 | 11 | ||
2011-05-03 | 2011-03-31 | -1.09 | -0.87 | 0.22 | 20 | ||
2011-02-03 | 2010-12-31 | -0.93 | -0.9 | 0.03 | 3 | ||
2010-10-25 | 2010-09-30 | -0.93 | -1.04 | -0.11 | 11 | ||
2010-07-28 | 2010-06-30 | -0.84 | -1.0 | -0.16 | 19 | ||
2010-04-21 | 2010-03-31 | -0.8 | -0.83 | -0.03 | 3 | ||
2010-02-04 | 2009-12-31 | -0.85 | -0.85 | 0.0 | 0 | ||
2009-10-26 | 2009-09-30 | -0.82 | -0.84 | -0.02 | 2 | ||
2009-08-05 | 2009-06-30 | -0.84 | -0.99 | -0.15 | 17 | ||
2009-04-16 | 2009-03-31 | -0.82 | -1.04 | -0.22 | 26 | ||
2009-02-09 | 2008-12-31 | -0.93 | -0.96 | -0.03 | 3 | ||
2008-10-27 | 2008-09-30 | -0.92 | -0.93 | -0.01 | 1 | ||
2008-07-31 | 2008-06-30 | -0.57 | -0.66 | -0.09 | 15 | ||
2008-04-21 | 2008-03-31 | -0.65 | -0.72 | -0.07 | 10 | ||
2008-02-11 | 2007-12-31 | -0.66 | -0.66 | 0.0 | 0 | ||
2007-10-29 | 2007-09-30 | -0.73 | -0.82 | -0.09 | 12 | ||
2007-07-24 | 2007-06-30 | -0.69 | -0.91 | -0.22 | 31 | ||
2007-04-30 | 2007-03-31 | -0.64 | -0.64 | 0.0 | 0 | ||
2007-02-01 | 2006-12-31 | -0.38 | -0.22 | 0.16 | 42 | ||
2006-10-26 | 2006-09-30 | -0.48 | -0.46 | 0.02 | 4 | ||
2006-07-26 | 2006-06-30 | -0.52 | -0.72 | -0.2 | 38 | ||
2006-04-25 | 2006-03-31 | -0.56 | -0.47 | 0.09 | 16 | ||
2006-02-07 | 2005-12-31 | -0.23 | -0.38 | -0.15 | 65 | ||
2005-10-26 | 2005-09-30 | -0.47 | -0.84 | -0.37 | 78 | ||
2005-07-27 | 2005-06-30 | -0.51 | -0.5 | 0.01 | 1 | ||
2005-04-26 | 2005-03-31 | -0.56 | -0.56 | 0.0 | 0 | ||
2005-02-09 | 2004-12-31 | -0.44 | -0.54 | -0.1 | 22 | ||
2004-10-25 | 2004-09-30 | -0.48 | -0.49 | -0.01 | 2 | ||
2004-07-26 | 2004-06-30 | -0.51 | -0.56 | -0.05 | 9 | ||
2004-04-26 | 2004-03-31 | -0.52 | -0.52 | 0.0 | 0 | ||
2004-02-11 | 2003-12-31 | -0.54 | -0.51 | 0.03 | 5 | ||
2003-11-10 | 2003-09-30 | -0.49 | -0.58 | -0.09 | 18 | ||
2003-07-24 | 2003-06-30 | -0.61 | -0.6 | 0.01 | 1 | ||
2003-04-24 | 2003-03-31 | -0.48 | -0.64 | -0.16 | 33 | ||
2003-02-04 | 2002-12-31 | -0.4 | -0.4 | 0.0 | 0 | ||
2002-11-04 | 2002-09-30 | -0.3 | -0.44 | -0.14 | 46 | ||
2002-07-18 | 2002-06-30 | -0.28 | -0.28 | 0.0 | 0 | ||
2002-04-24 | 2002-03-31 | -0.28 | -0.29 | -0.01 | 3 | ||
2002-02-07 | 2001-12-31 | -0.19 | -0.15 | 0.04 | 21 | ||
2001-10-24 | 2001-09-30 | -0.27 | -0.18 | 0.09 | 33 | ||
2001-07-27 | 2001-06-30 | -0.26 | -0.16 | 0.1 | 38 | ||
2001-04-24 | 2001-03-31 | -0.31 | -0.15 | 0.16 | 51 | ||
2001-02-22 | 2000-12-31 | -0.14 | -0.04 | 0.1 | 71 | ||
2000-10-24 | 2000-09-30 | -0.22 | -0.46 | -0.24 | 109 | ||
2000-07-26 | 2000-06-30 | 0.21 | 0.22 | 0.01 | 4 | ||
2000-05-11 | 2000-03-31 | -0.29 | -0.31 | -0.02 | 6 | ||
2000-02-16 | 1999-12-31 | 0.01 | 0.03 | 0.02 | 200 | ||
1999-10-27 | 1999-09-30 | -0.25 | -0.28 | -0.03 | 12 | ||
1999-07-27 | 1999-06-30 | -0.19 | -0.21 | -0.02 | 10 | ||
1999-04-21 | 1999-03-31 | -0.3 | -0.34 | -0.04 | 13 | ||
1999-02-25 | 1998-12-31 | -0.21 | -0.25 | -0.04 | 19 | ||
1998-10-21 | 1998-09-30 | -0.09 | -0.04 | 0.05 | 55 | ||
1998-07-22 | 1998-06-30 | -0.15 | -0.19 | -0.04 | 26 | ||
1998-04-22 | 1998-03-31 | -0.16 | -0.16 | 0.0 | 0 | ||
1998-02-23 | 1997-12-31 | -0.15 | -0.13 | 0.02 | 13 | ||
1997-10-21 | 1997-09-30 | -0.14 | -0.11 | 0.03 | 21 | ||
1997-07-22 | 1997-06-30 | -0.12 | -0.03 | 0.09 | 75 | ||
1997-04-22 | 1997-03-31 | -0.15 | -0.13 | 0.02 | 13 | ||
1997-02-19 | 1996-12-31 | -0.16 | -0.09 | 0.07 | 43 | ||
1996-10-23 | 1996-09-30 | -0.19 | -0.16 | 0.03 | 15 | ||
1996-07-26 | 1996-06-30 | -0.18 | -0.21 | -0.03 | 16 | ||
1996-04-25 | 1996-03-31 | -0.17 | -0.21 | -0.04 | 23 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Vertex Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Vertex Pharmaceuticals Corporate Directors
Vertex Pharmaceuticals corporate directors refer to members of a Vertex Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Vertex Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Vertex Pharmaceuticals' board members must vote for the resolution. The Vertex Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| William Young | Independent Director | Profile | |
| Alan Garber | Independent Director | Profile | |
| Margaret McGlynn | Independent Director | Profile | |
| Sangeeta Bhatia | Director | Profile |
How to buy Vertex Stock?
The net worth of Vertex Pharmaceuticals is the difference between its total assets and liabilities. Vertex Pharmaceuticals' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Vertex Pharmaceuticals' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Vertex Pharmaceuticals' net worth can be used as a measure of its financial health and stability which can help investors to decide if Vertex Pharmaceuticals is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Vertex Pharmaceuticals stock.Already Invested in Vertex Pharmaceuticals?
The danger of trading Vertex Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Vertex Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Vertex Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Vertex Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Vertex Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vertex Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vertex Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vertex Pharmaceuticals Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.181 | Earnings Share 13.87 | Revenue Per Share 38.297 | Quarterly Revenue Growth 0.093 | Return On Assets 0.1317 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.